Adverse Reactions in Antifolate-Treated Toxoplasmic Retinochoroiditis.

[1]  D. Rabczenko,et al.  The Impact of Short-Term, Intensive Antifolate Treatment (with Pyrimethamine and Sulfadoxine) and Antibiotics Followed by Long-Term, Secondary Antifolate Prophylaxis on the Rate of Toxoplasmic Retinochoroiditis Recurrence , 2016, PLoS neglected tropical diseases.

[2]  A. Curi,et al.  Toxoplasmic Retinochoroiditis: Clinical Characteristics and Visual Outcome in a Prospective Study , 2016, PLoS neglected tropical diseases.

[3]  R. Rozen,et al.  High Dietary Folate in Mice Alters Immune Response and Reduces Survival after Malarial Infection , 2015, PloS one.

[4]  P. Carvounis,et al.  Current Treatment of Toxoplasma Retinochoroiditis: An Evidence-Based Review , 2014, Journal of ophthalmology.

[5]  A. Nzila,et al.  Impact of folate supplementation on the efficacy of sulfadoxine/pyrimethamine in preventing malaria in pregnancy: the potential of 5-methyl-tetrahydrofolate. , 2014, The Journal of antimicrobial chemotherapy.

[6]  K. Balaskas,et al.  Azithromycin versus Sulfadiazine and Pyrimethamine for non-vision-threatening toxoplasmic retinochoroiditis: A pilot study , 2012, Medical science monitor : international medical journal of experimental and clinical research.

[7]  D. Wakefield,et al.  Controversies in Ocular Toxoplasmosis , 2011, Ocular immunology and inflammation.

[8]  A. Smith,et al.  Is folic acid good for everyone? , 2008, The American journal of clinical nutrition.

[9]  G. Peyman,et al.  Prospective randomized trial of trimethoprim/sulfamethoxazole versus pyrimethamine and sulfadiazine in the treatment of ocular toxoplasmosis. , 2005, Ophthalmology.

[10]  W. Watkins,et al.  Reduction of the efficacy of antifolate antimalarial therapy by folic acid supplementation. , 2005, The American journal of tropical medicine and hygiene.

[11]  F. Verbraak,et al.  A prospective, randomized trial of pyrimethamine and azithromycin vs pyrimethamine and sulfadiazine for the treatment of ocular toxoplasmosis. , 2002, American journal of ophthalmology.

[12]  G. Holland,et al.  An update on current practices in the management of ocular toxoplasmosis. , 2002, American journal of ophthalmology.

[13]  R. Gilbert,et al.  Antibiotics versus control for toxoplasma retinochoroiditis. , 2002, The Cochrane database of systematic reviews.

[14]  J. Roujeau,et al.  Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death? , 2000, Archives of dermatology.

[15]  A. Rothova,et al.  Sense and nonsense of corticosteroid administration in the treatment of ocular toxoplasmosis , 1998, The British journal of ophthalmology.

[16]  T. Vree,et al.  Adverse reactions to co-trimoxazole in HIV infection: a reappraisal of the glutathione-hydroxylamine hypothesis. , 1996, The Journal of antimicrobial chemotherapy.

[17]  Theresa Anderson,et al.  Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis , 1995 .

[18]  P T de Jong,et al.  Therapy of ocular toxoplasmosis. , 1993, International ophthalmology.

[19]  F. Derouin,et al.  Synergistic activity of azithromycin and pyrimethamine or sulfadiazine in acute experimental toxoplasmosis , 1992, Antimicrobial Agents and Chemotherapy.

[20]  J. Remington,et al.  In vivo activity of the macrolide antibiotics azithromycin, roxithromycin and spiramycin againstToxoplasma gondii , 1991, European Journal of Clinical Microbiology and Infectious Diseases.

[21]  M. Lorca,et al.  A comparative study of some combined treatment regimens in acute toxoplasmosis in mice. , 1978, The American journal of tropical medicine and hygiene.

[22]  Justine R. Smith,et al.  Ocular toxoplasmosis II: clinical features, pathology and management , 2013, Clinical & experimental ophthalmology.

[23]  C. Ponticelli,et al.  Pharmacokinetic study of the new sulfamethopyrazine-trimethoprim combination (kelfiprim) in renal insufficiency , 2004, European Journal of Clinical Pharmacology.

[24]  G. Holland.  Ocular toxoplasmosis: a global reassessment. Part II: disease manifestations and management. , 2004, American journal of ophthalmology.

[25]  U. Dubach,et al.  Plasma concentrations in pyrimethamine and sulfadoxine and evaluation of pharmacokinetic data by computerized curve fitting. , 1982, Bulletin of the World Health Organization.